GT Biopharma, Inc.

GRI Bio, Inc.

Cartesian Therapeutics, Inc.

Viridian Therapeutics, Inc.

Jazz Pharmaceuticals plc

Compass Therapeutics, Inc.

SpyGlass Pharma, Inc.

Summit Therapeutics Inc.

Generate Biomedicines, Inc.

Dilution score: 53/100 (HIGH), 17.2 months cash

13F fund flow: neutral, ? institutional managers

79 PubMed publications found for GT Biopharma, .

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Biomarker study of pembrolizumab in patients with advanced rare cancers.

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Short interest: 10.21% of float, squeeze risk: LOW

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="GTBP">
<p>GT Biopharma, Inc. (GTBP) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for GTBP were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0000109657 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22GTBP%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0000109657

GT Biopharma, Inc. (GTBP) — BioTechSigns Verified Summary

GT Biopharma, Inc. (GTBP) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for GTBP were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0000109657. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22GTBP%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17